Previous close | 69.73 |
Open | 69.73 |
Bid | 69.78 x 100 |
Ask | 70.05 x 100 |
Day's range | 69.34 - 71.00 |
52-week range | 38.14 - 89.39 |
Volume | |
Avg. volume | 482,680 |
Market cap | 4.507B |
Beta (5Y monthly) | 1.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted therapies for patients with cancer, has reported an insider sale according to a recent SEC filing.
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.